Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial
- 1 August 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (8) , 1856-1865
Abstract
Background: Hypertension, endothelial dysfunction, and inflammation are associated with increased cardiovascular mortality in end-stage kidney disease. We evaluated the effects of ACE (angiotensin-converting enzyme) inhibition on biomarkers of endothelial dysfunction and inflammation in hypertensive children with end-stage kidney disease on maintenance hemodialysis. Methods: In a randomized, double-blind, placebo-controlled trial, 135 (72 males/63 females) children and adolescents (age 7–15 years) were randomly assigned to treatment with either 2.5 mg once daily ramipril (n=68) or placebo (n=67) for 16 weeks. Primary outcome were the serum concentrations of asymmetrical dimethylarginine, a marker of endothelial dysfunction and hs-CRP (high-sensitivity C-reactive protein), a marker of inflammation. Changes in IL-6 (interleukin-6), TNF-α (tumor necrosis factor-alpha), systolic (S), and diastolic (D) blood pressure were secondary outcomes. Change in potassium levels and incidence of hyperkalemia were among the safety parameters. Results: Ramipril, but not placebo, significantly reduced serum levels of asymmetrical dimethylarginine (−79.6%; P P P P P <0.001, respectively). Changes in asymmetrical dimethylarginine, hs-CRP, IL-6, or TNF-α in the ramipril group did not significantly correlate with blood pressure reductions. No severe cases of hyperkalemia or other serious treatment-associated adverse events were observed. Conclusions: Ramipril improves biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis in addition to its efficacious and safe potential to lower blood pressure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04582097.Keywords
This publication has 45 references indexed in Scilit:
- Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during HemodialysisJournal of the American Society of Nephrology, 2012
- A Comparison of the Antihypertensive and Anti-Inflammatory Effects of Aliskiren and Ramipril Add-On Therapy in Peritoneal Dialysis Patients – A Pilot Open Label StudyKidney and Blood Pressure Research, 2012
- The role of asymmetric and symmetric dimethylarginines in renal diseaseNature Reviews Nephrology, 2011
- Hypertension in Pediatric Long-term Hemodialysis Patients in the United StatesClinical Journal of the American Society of Nephrology, 2009
- KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 UpdateAmerican Journal of Kidney Diseases, 2009
- Review: The therapeutic role of RAS blockade in chronic heart failureTherapeutic Advances in Cardiovascular Disease, 2008
- Improving Proteinuria, Endothelial Functions and Asymmetric Dimethylarginine Levels in Chronic Kidney Disease: Ramipril versus ValsartanBlood Purification, 2007
- Inflammatory Syndrome in Patients on HemodialysisJournal of the American Society of Nephrology, 2006
- Long-Term Survival of Children with End-Stage Renal DiseaseNew England Journal of Medicine, 2004
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003